Human IL13RA2 Protein (C-Fc-Avi) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95% based on reducing conditions.
Cat #
Size
Price
Quantity
804801
25 ug
$145
804802
100 ug
$295
Product Details
Application
ELISA, BLI
Format
Liquid, Purified
Expression Host
CHO
Target Name
IL13RA2, CD213A2, IL-13R, IL13BP
Species
Human
Sources
Recombinant Human IL13RA2 protein (Cys22-Leu342) with C-terminus Fc-Avi tag is expressed in CHO cells.
accession number
Q14627
Molecular Weight
The protein has a predicted molecular weight of 65.7 kDa. Under DTT-reducing conditions, it migrates at approximately 65-80 kDa on SDS-PAGE.
Affinity Tag
C-Fc-Avi
Purity
>95% based on SDS-PAGE under reducing condition
Formulation
1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level
Not tested
Protein Concentration
25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling
Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.
Background Information
CD213A2, also known as IL13Rα2, is a type I transmembrane protein belonging to the hematopoietin receptor family. It binds interleukin-13 (IL-13) with high affinity but lacks a functional cytoplasmic signaling domain, suggesting that it primarily acts as a decoy receptor, antagonizing IL-13 signaling mediated by the IL-13Rα1/IL-4Rα complex. IL13Rα2 is expressed in fibroblasts, smooth muscle cells, keratinocytes, and activated B cells, though its surface expression is tightly regulated and much of it resides intracellularly or in soluble form. In addition to inhibiting IL-13 activity, IL13Rα2 has been reported to suppress IL-4 signaling via physical interaction with IL-4Rα, while paradoxically promoting TGF-β production and fibrosis. Importantly, IL13Rα2 is highly and specifically overexpressed in certain cancers, such as glioblastoma multiforme and high-grade astrocytomas, making it a promising target for tumor-specific immunotherapies and viral vector-mediated gene delivery approaches.
Human IL13RA2 Protein (C-Fc-Avi) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95% based on reducing conditions.
